iodohippurate sodium i-123
Trade name: Nephroflow
Small moleculeapprovedImaging agent
Approved
Dec 28, 1984
I-123 radiolabeled ortho-iodohippurate is commonly employed for evaluating effective renal plasma flow (ERPF) by means of either in vivo scintigraphy and/or plasma clearance curves. It has been used to evaluate renal functioning in patients with obstructive uropathy, vesicorenal reflux, hypertensiion due to renal artery stenosis. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1980s
- Dec 28, 1984
General Electric — Earliest FDA Approval
- Dec 28, 1984
General Electric — NDA Organization
- Dec 28, 1984
General Electric — Marketing Organization
Indications
Approved for
Mechanism of action
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedDec 28, 1984
Chemistry & pharmacology
Loading structure…
SMILES
OC(=O)CNC(=O)C1=CC=CC=C1[123I]- Mol. weight
- 301.0703 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
- Imaging
- 123-Iodine
Oral
No
Parenteral
Yes
Topical
No
Sources
- NCATSG4586WF35M ↗
- ChEMBLCHEMBL1200439 ↗
Also known as
- iodohippurate sodium i 123
- iodohippurate sodium i 123
- iodohippurate sodium i-123
- iodohippurate sodium i-123
- iodohippurate sodium i-123
- nephroflow
- nephroflow
- nephroflow
- sodium iodohippurate (123i)
- sodium iodohippurate (123i)
- sodium o-iodo-(123i)-hippurate
- sodium o-iodo-(123i)-hippurate
Organizations
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| General Electric | For profit | NDA | Dec 28, 1984 |
| General Electric | For profit | MKTG | Dec 28, 1984 |